Below-floor business quality, negative free cash flow, and a share price that has already exceeded its near-term resistance target combine to create an unattractive risk profile, even as a four-quarter earnings beat streak and strong price momentum indicate the story retains near-term speculative interest.
Thesis pillars
- Quality Deficiency Cash Burn→Stable
- Price Exceeded Resistance Target↑Improving
- Elevated Short Interest Bearish Positioning↑Improving
- +1 more pillar — see the Why tab for full reasoning
Moderna, Inc. (MRNA) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $56.15: Quality below floor (3.1 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.6/10. Specifically: High short interest: 16%; Below-average business quality; Rich valuation.
Moderna develops mRNA-based vaccines and therapeutics, currently commercializing three respiratory products — Spikevax, mNEXSPIKE (COVID-19), and mRESVIA (RSV) — that generated $1.9 billion in total revenue in 2025. Revenue is earned from product sales to government and... Read more
Sell if holding. Engine safety override at $56.15: Quality below floor (3.1 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.6/10. Specifically: High short interest: 16%; Below-average business quality; Rich valuation. Chart setup: No clear chart pattern; technical signals are mixed. Score 4.6/10, moderate confidence.
Passes 5/8 gates (clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio and earnings proximity 4d<=7d. Suitability: speculative.
About Moderna, Inc.
About Moderna, Inc.
Moderna's three commercialized respiratory vaccines — Spikevax and mNEXSPIKE (COVID-19) and mRESVIA (RSV) — generated $1.9 billion in total revenue in 2025, with mNEXSPIKE launched commercially in the third quarter of 2025 and becoming Moderna's leading product in the U.S. retail channel by year-end. Regulatory filings for a seasonal flu+COVID combination vaccine (mRNA-1083) are under review in Europe and Canada, and for a standalone flu vaccine (mRNA-1010) in the United States, Europe, Canada, and Australia, with the FDA assigning mRNA-1010 a PDUFA goal date of August 5, 2026. The company carries a 35-program pipeline, 6 of which are in late-stage development.
Moderna earns revenue primarily from product sales of COVID and RSV vaccines, competing against Pfizer and Sanofi for COVID market share and against Pfizer and GSK in RSV. The company has been excluded from selling COVID vaccines in many European markets due to a competitor's contract with the European Commission that does not lapse until year-end 2026, limiting near-term geographic expansion. Beyond vaccines, the oncology pipeline is anchored by intismeran autogene (mRNA-4157), a personalized neoantigen therapy advancing in collaboration with Merck across eight Phase 2 and Phase 3 trials; in January 2026, five-year Phase 2b data demonstrated sustained improvement in recurrence-free survival in high-risk melanoma patients. The company plans to fund oncology and rare disease investments from cash generated by the infectious disease franchise as it expands toward a planned six approved products.
Show full overview
The most consequential near-term regulatory binary is the FDA review of mRNA-1010 (standalone flu vaccine), PDUFA August 5, 2026. Following a prior Refusal-to-File letter, Moderna submitted an amended BLA seeking full approval for adults 50-64 and accelerated approval for adults 65 and older. Non-approval or a restricted label could delay the company's plan to expand its commercial franchise and may weigh on its ability to reach cash breakeven — a stated near-term strategic goal — by limiting the revenue base available to fund the oncology and rare disease pipeline.
See also: Healthcare · Biotechnology
From Moderna, Inc.'s most recent 10-K filing, extracted June 11, 2026.
Recent developments
updated 2026-07-27Recent Developments — Moderna, Inc.
Latest news
- NEWS Goldman Sachs Maintains Neutral on Moderna, Raises Price Target to $67 — benzinga Jul 21, 2026 positive
- NEWS Moderna Doses First US Participant In Its Phase 1 Study Of mRNA-4200, Tumor-Targeted Cancer Antigen Therapy Candidate, F — benzinga Jul 16, 2026 positive
- NEWS Intel Stock Has Doubled, So Why Is JPMorgan Calling It a Top Short? — benzinga Jul 10, 2026 negative
- NEWS 9 Health Care Stocks Whale Activity In Today’s Session — benzinga Jul 8, 2026 neutral
- NEWS Morgan Stanley Maintains Equal-Weight on Moderna, Raises Price Target to $39 — benzinga Jul 8, 2026 neutral
Generated 2026-07-27T18:52:51Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMProductCOVID vaccines10-K Item 1: 'In 2025, we achieved total revenue of $1.9 billion, largely from sales of our COVID vaccines'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Clinical-stage biotech: losses expected pre-commercialisation. Quality floor doesn't distinguish R&D investment from operational decay — components above tell the real story.static
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $56.15: Quality below floor (3.1 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.6/10. Specifically: High short interest: 16%; Below-average business quality; Rich valuation. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $52.25. Score 4.6/10, moderate confidence.
Take-profit target: $83.89 (-20.9% upside). Prior stop was $52.25. Stop-loss: $52.25.
Target reached (-20.9% upside); Quality below floor (3.1 < 4.0); Value-trap signals (2/5): Margin compression (op margin -12.4%), Material insider selling (124 sells, 0.20% of cap).
Moderna, Inc. trades at a P/E of N/A (forward -12.9). TrendMatrix value score: 3.3/10. Verdict: Sell.
30 analysts cover MRNA with a consensus score of 2.8/5. Average price target: $49.
What does Moderna, Inc. do?Moderna develops mRNA-based vaccines and therapeutics, currently commercializing three respiratory products — Spikevax,...
Moderna develops mRNA-based vaccines and therapeutics, currently commercializing three respiratory products — Spikevax, mNEXSPIKE (COVID-19), and mRESVIA (RSV) — that generated $1.9 billion in total revenue in 2025. Revenue is earned from product sales to government and commercial channels, with COVID vaccines accounting for the majority of current income and a 35-program pipeline targeting oncology, rare disease, and infectious disease.